- AIML (AIMLF, Financial) establishes a Medical Advisory Board for its AI-driven ECG platforms.
- The board includes six renowned cardiovascular experts from leading institutions.
- A new corporate website, AIML.Health, has been launched to engage stakeholders.
AIML Innovations Inc. (AIMLF) has announced the formation of its Medical Advisory Board to advance the development and application of its AI-powered ECG signal-processing technologies, MaxYield™ and CardioYield™. The board, composed of six distinguished cardiovascular specialists from esteemed institutions such as the University of Toronto and the University of British Columbia, aims to provide clinical direction, design trials, and oversee the real-world deployment of these flagship platforms.
Peter Kendall, President and Chief Commercialization Officer of AIML, will chair the board. With over 20 years of experience in health technology commercialization, Kendall is poised to integrate clinical expertise with AIML's strategic initiatives, ensuring the alignment of scientific guidance with market needs.
The Medical Advisory Board features prominent figures including Dr. Paul Dorian and Dr. Alan Rabinowitz, among others, who will provide invaluable insights into clinical studies and regulatory pathways. Their combined expertise is expected to drive the global adoption of AIML's solutions in wearables and cardiology workflows.
In conjunction with the board's formation, AIML has launched its redesigned corporate website, AIML.Health, which will serve as an interactive hub for investors, partners, and other stakeholders. This digital platform aims to foster engagement and provide comprehensive resources about AIML's initiatives and advancements.
AIML Innovations Inc., a pioneer in leveraging artificial intelligence for digital health, continues its commitment to transforming biometric data into actionable clinical insights through advanced signal processing and deep learning technologies. The company is actively pursuing regulatory validations to expand its solutions' reach and efficacy in the healthcare sector.
